4,059 reports of this reaction
26.7% of all EMICIZUMAB reports
#1 most reported adverse reaction
HAEMORRHAGE is the #1 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 4,059 FDA adverse event reports linking EMICIZUMAB to HAEMORRHAGE. This represents approximately 26.7% of all 15,224 adverse event reports for this drug.
Patients taking EMICIZUMAB who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is a frequently reported adverse event for EMICIZUMAB, accounting for a significant proportion of all reports.
In addition to haemorrhage, the following adverse reactions have been reported for EMICIZUMAB:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 4,059 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 26.7% of all adverse event reports for EMICIZUMAB, making it one of the most commonly reported side effect.
If you experience haemorrhage while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.